These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24840057)

  • 1. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play?
    Rockstroh JK; Mohr R; Behrens G; Spengler U
    Curr Opin HIV AIDS; 2014 Jul; 9(4):365-70. PubMed ID: 24840057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.
    Blanco F; Barreiro P; Ryan P; Vispo E; Martín-Carbonero L; Tuma P; Labarga P; Medrano J; González-Lahoz J; Soriano V
    J Viral Hepat; 2011 Jan; 18(1):11-6. PubMed ID: 20088890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.
    Castellares C; Barreiro P; Martín-Carbonero L; Labarga P; Vispo ME; Casado R; Galindo L; García-Gascó P; García-Samaniego J; Soriano V
    J Viral Hepat; 2008 Mar; 15(3):165-72. PubMed ID: 18233989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a need for liver disease monitoring in HIV patients in Africa?
    Rockstroh JK; Peters L; Wedemeyer H
    Antivir Ther; 2011; 16(3):287-9. PubMed ID: 21555810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Immune activation, aging and gender" and progression of liver disease.
    Nasta P
    Acta Biomed; 2011 Aug; 82(2):115-23. PubMed ID: 22480066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver stiffness values in HIV-infected patients with isolated anti-hepatitis B core antibodies.
    Chakvetadze C; Bani-Sadr F; Lescure FX; Fontaine C; Le Pendeven C; Bonnard P; Mariot P; Soussan P; Pialoux G
    Med Mal Infect; 2013 Jun; 43(6):222-5. PubMed ID: 23597924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The liver in HIV in Africa.
    Feld JJ; Ocama P; Ronald A
    Antivir Ther; 2005; 10(8):953-65. PubMed ID: 16430201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.
    Andreoni M; Giacometti A; Maida I; Meraviglia P; Ripamonti D; Sarmati L
    Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1473-83. PubMed ID: 23111959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human immunodeficiency virus infection and viral hepatitis].
    Soriano V; Martin-Carbonero L; Vispo E; Labarga P; Barreiro P
    Enferm Infecc Microbiol Clin; 2011 Nov; 29(9):691-701. PubMed ID: 21978797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV.
    Marcus KA; Sorbello A; Truffa M; Williams J; Raine JM; Powderly WG
    Curr Opin HIV AIDS; 2012 Jul; 7(4):292-8. PubMed ID: 22647589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV and viral hepatitis coinfections: advances and challenges.
    Lacombe K; Rockstroh J
    Gut; 2012 May; 61 Suppl 1():i47-58. PubMed ID: 22504919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
    Calin R; Guiguet M; Desire N; Imbert-Bismut F; Munteanu M; Poynard T; Valantin MA; Stitou H; Katlama C; Thibault V
    J Clin Virol; 2013 Oct; 58(2):408-14. PubMed ID: 23958588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies.
    Falutz J
    Curr Opin Clin Nutr Metab Care; 2011 May; 14(3):255-60. PubMed ID: 21460720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of hepatitis C in HIV-coinfection.
    Rockstroh JK; Vogel M
    Eur J Med Res; 2004 Jun; 9(6):304-8. PubMed ID: 15257871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.